Compared to those on CD4+ T cells in PBMCs, the expression levels of antitumor (TNFβ, T-bet, and granzyme B) and protumor (PD-1 and IL-10) markers on CD4+ T cells in tumor sites were commonly higher (Figure 3F). This evidence concerns the gene IL10 and neoplasm.